

Device Incident Report 23483 - Eska Implants

04/06/2011 12:45 AM

Cc:

Hide Details

From:

To:

Cc:

Dear

I am writing from Orthodynamics GmbH with regard to the above incident.

In April 2010, The Summit Medical Group acquired the assets of Eska Implants AG and formed the new business of Orthodynamics GmbH. I am therefore carrying out the incident investigation alongside our Australian sponsors ESKA Australia.

Unfortunately, there is now a holiday period in Germany which means that I am not able to submit the full results of our investigation today as planned. However, I will be in a position to submit all of the documents on Monday, which means they will be with you on Tuesday morning.

Please accept my apologies for this inconvenience.

Kind regards,

Kilia regara

Leiter Qualitätsmanagement und Regulatory Affairs – Implantate Quality Management and Regulatory Affairs Manager – Implants

Orthodynamics GmbH Grapengießerstraße 34 23556 Lübeck Germany Telefon:
Mobil:
Fax:
E-Mail:
Internet:

Sitz der Gesellschaft: Lübeck | Amtsgericht Lübeck HRB 10091 | USt.-Id.-Nr.: DE 815 171 654 Geschäftsführung: Frank Collins, Darren Gates, Ralf Okonnek

Für mehr Informationen besuchen Sie bitte...

Orthodynamics Ltd. 10 Airfield Road Christchurch, Dorset, BH23 3TG, UK Telefon:

Fax: E-Mail: info@orthodynamics.co.uk Internet: www.orthodynamics.co.uk

Summit Medical Ltd. Industrial Park, Bourton on the Water, Gloucestershire, GL54 2HQ, UK

Telefon:

Fax: E-Mail: info@summit-medical.co.uk Internet: www.summit-medical.co.uk

Please see our web page for our registered office, number and certification. The information contained in this e-mail message is intended only for the individuals named above. If you are not the intended recipient, you should be aware that any dissemination, distribution, forwarding or other duplication of this communication is strictly prohibited. The views expressed in this e-mail are those of the individual author and not necessarily those of the Summit Medical group. Prior to taking any action based upon this e-mail message you should seek appropriate confirmation of its authenticity. If you have received this e-mail in error, please immediately notify the sender by using the e-mail reply facility.



<u>To</u>: Cc:

Bcc:

Subject: Re: DIR 23483 [SEC=UNCLASSIFIED]

Dear

An extension is granted for the information required of an additional five days. Please fill out the questionnaire with as much information as possible and provide a date in section 10 that the manufacturer believes their investigation/ analysis will be ready for review

The information is now due on 3 June 2011

Kind regards

IRIS Coordinator - Device Vigilance & Monitoring |Office of Product Review |Therapeutic Goods Administration

uri, <u>www.tga.gov.au</u>

Post: PO Box 100, Woden, ACT 2606 | Courier: 136 Narrabundah Lane, Symonston, ACT 2609

Dear

Thank you for your email

24/05/2011 09:57:11 AM

From:

To: Date: Subject:

24/05/2011 09:57 AM

Re: DIR 23483 [SEC=UNCLASSIFIED]

Dear

Thank you for your email

My company protocol is that I send any request from the TGA to the mother company in Germany

The company in Germany have requested an extension! Is this possible?

Kind Regards

Dear		
Please attached lette	r	
	r information regarding the reporti ties for placing devices on the ARTO	-
	au/industry/devices-argmd.htm < au/industry/devices-argmd.htm>	
	au/industry/devices.htm < au/industry/devices.htm>	
Kind regards		
	- Device Vigilance & Monitoreds Administration	ring Office of Product F
		url:
	 http://www.tga.gov.au/"> Woden, ACT 2606 Courie	


.

.

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information and has been sent in accordance with the TGA security policy.

If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author Immediately and delete all copies of this transmission."





This email message and any accompanying attachments may contain information that is confidential and subject to legal privilege. If you are not the intended recipient, do not read, use, disseminate, distribute or copy this message and its attachments. If you have received this message in error, please notify the sender immediately and delete this message. Any views expressed in this message are those of the individual sender, except where the sender express, and with authority, states them to be the views of the writer. This email cannot be shared with any outside third party other than those that this email has been written to, unless permission has been given by the writer, in accordance with privacy laws.